Cancer today [Internet]. [cited 2022 Feb 27]. Available from: https://gco.iarc.fr/today/home.

Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare).

Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial risk and heritability of Cancer among Twins in Nordic Countries. JAMA. 2016;315:68–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105:1230–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010;16:2115–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Helgason H, Rafnar T, Olafsdottir HS, Jonasson JG, Sigurdsson A, Stacey SN, et al. Loss-of-function variants in ATM confer risk of gastric cancer. Nat Genet. 2015;47:906–10.

Article  CAS  PubMed  Google Scholar 

Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:437–49.

Article  CAS  PubMed  Google Scholar 

Dominguez-Valentin M, Sampson JR, Seppälä TT, Ten Broeke SW, Plazzer J-P, Nakken S, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch Syndrome Database. Genet Med. 2020;22:15–25.

Article  CAS  PubMed  Google Scholar 

Bancroft EK, Page EC, Brook MN, Thomas S, Taylor N, Pope J, et al. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncol. 2021;22:1618–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310–6.

Article  Google Scholar 

Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.

Article  CAS  PubMed  Google Scholar 

Raymond VM, Mukherjee B, Wang F, Huang S-C, Stoffel EM, Kastrinos F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol. 2013;31:1713–8.

Article  PubMed  PubMed Central  Google Scholar 

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, et al. Efficacy of Pembrolizumab in patients with Noncolorectal high microsatellite Instability/Mismatch repair–deficient Cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10.

Article  CAS  PubMed  Google Scholar 

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair gene mutations in men with metastatic prostate Cancer. N Engl J Med. 2016;375:443–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amin MB, Edge SB, Greene FL, Byrd DR. AJCC Cancer Staging Manual. Springer International Publishing; 2017.

Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40:244–52.

Bennett RL, French KS, Resta RG, Doyle DL. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of genetic counselors. J Genet Couns. 2008;17:424–33.

Article  PubMed  Google Scholar 

Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol. 2005;6:980–7.

Article  PubMed  Google Scholar 

Kagawa M, Kawakami S, Yamamoto A, Suzuki O, Eguchi H, Okazaki Y, et al. Prevalence and clinicopathological/molecular characteristics of mismatch repair protein-deficient tumours among surgically treated patients with prostate cancer in a japanese hospital-based population. Jpn J Clin Oncol. 2021;51:639–45.

Article  PubMed  Google Scholar 

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, et al. Analysis of the prevalence of microsatellite instability in prostate Cancer and response to Immune Checkpoint Blockade. JAMA Oncol. 2019;5:471–8.

Article  PubMed  Google Scholar 

South CD, Hampel H, Comeras I, Westman JA, Frankel WL, de la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst. 2008;100:277–81.

Article  CAS  PubMed  Google Scholar 

Roberts ME, Riegert-Johnson DL, Thomas BC, Rumilla KM, Thomas CS, Heckman MG, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the muir–torre variant of Lynch syndrome. Genet Med. 2014;16:711–6.

Article  PubMed  Google Scholar 

Antonarakis ES, Shaukat F, Isaacsson Velho P, Kaur H, Shenderov E, Pardoll DM, et al. Clinical features and therapeutic outcomes in men with advanced prostate Cancer and DNA mismatch repair gene mutations. Eur Urol. 2019;75:378–82.

Article  CAS  PubMed  Google Scholar 

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, et al. MSH2 loss in primary prostate Cancer. Clin Cancer Res. 2017;23:6863–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pearlman R, Frankel WL, Swanson BJ, Jones D, Zhao W, Yilmaz A et al. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. JCO Precis Oncol [Internet]. 2021;5. https://doi.org/10.1200/PO.20.00525.